Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of graft-versus-host disease

a technology of graft and host disease, applied in the direction of skeletal/connective tissue cells, immunological disorders, peptide/protein ingredients, etc., can solve the problems of patient death, agvhd requires a different approach, and liver function problems

Active Publication Date: 2016-06-16
SCM LIFESCI CO LTD
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The method effectively treats cGVHD symptoms by reducing T-cell activity and improving patient conditions, as demonstrated by reduced stool volume and normalized alkaline phosphatase levels, with no adverse reactions observed during clinical trials.

Problems solved by technology

Namely, it is a disease that is induced by living lymphocytes which were transfused causing an immune reaction that leads to problems in liver function, skin lesions, jaundice, diarrhea, fever, pancytopenia, and so on, and in severe cases patient death.
Because cGVHD and aGVHD are not successive diseases, aGVHD requires a different approach and cGVHD is becoming the bigger problem due to developments in blood and marrow progenitor cell transplantation therapeutic methods.
Aside from that, the gall bladder duct is diminished, and while bile accumulation can be seen, because there may be cases in which it may be mixed with legions related to the medication or viral hepatitis, there may be cases in which it is difficult to differentiate from cGVHD.
However, because MSC that exists in the body is very rare, development of technology that isolates it is important.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of graft-versus-host disease
  • Treatment of graft-versus-host disease
  • Treatment of graft-versus-host disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Separation of Mesenchymal or Marrow Stem Cells Using Subfractionation Culturing Method

[0079]After applying local anesthesia to a section of the marrow provider's (mother of treatment target chronic graft-versus-host disease patient) hip, bone marrow was extracted by inserting an injection needle into the hip bone. 15 ml of DMEM (Dulbecco's modified Eagle's Medium, GIBCO-BRL, Life-technologies, MD, USA) which included 20% FBS and 1% penicillin / streptomycin and 2 ml of the marrow extracted from the above mentioned marrow provider was put into a 100 mm culture container and cultivated for 2 hours in a 37° C., 5% CO2 cell cultivator. After cultivation, the culture container was slightly leaned so that the cells attached to the bottom would not fall out and the maximum amount of the upper layer culture liquid in the culture container was moved to a new container.

[0080]After repeating the same procedure once more the culture liquid that was taken was moved to a culture container (Becton D...

example 2

Verification of Separated Mesenchymal or Marrow Stem Cells

example 2.1

Analysis of Mesenchymal or Marrow Stem Cell Characteristics Using Flow Cytometry

[0082]In order to verify whether the cMSC-15 cells that were separated from the marrow using the method in the above Example 1 were mesenchymal or marrow stem cells, a flow cytometry (BD Biosciences) was used to find out if cell surface antigens with stem cell characteristics existed.

[0083]Stem cells that were successively cultivated for 6 to 7 days in a 75 cm2 culture container was treated with 0.25% trypsin and the cells were gathered. The cells were washed 2 times with a 1×PBS / 0.4% BSA to remove trypsin as well as culture liquids. The cells were collected using centrifugal separation and after measuring the number of cells, 1×106 cells were gathered in a 1.5 ml tube and blocked for 1 hour in room temperature using goat serum (Vector). After the completion of blocking, the cells were washed 2 times with a 1×PBS / 0.4% BSA and treated with a phycoerythrin (PE) attached anti-CD14, CD29, CD31, CD34, CD44, C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

This present application describes a therapeutic agent for treating acute or chronic graft-versus-host disease using clonal marrow stem cells (cMSCs) as active ingredient.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application claims the benefit of priority to U.S. Provisional Patent Application No. 60 / 940,349, filed May 25, 2007, the contents of which are incorporated by reference herein in their entirety.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates to a therapeutic agent for treating acute or chronic graft-versus-host disease. The present invention also relates to a therapeutic agent for treating acute or chronic graft-versus-host disease that contains mesenchymal stem cells as an active ingredient.[0004]2. General Background and State of the Art[0005]Graft-versus-host disease (GVHD) refers to a disease wherein the body of the patient has an immune reaction to the donor's peripheral blood or the T lymphocytes in the bone marrow that are injected during homogeneous transplantation. Namely, it is a disease that is induced by living lymphocytes which were transfused causing an immune reacti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/28C12N5/0775A61K35/17A61P37/02
CPCA61K35/28C12N5/0663A61K35/17A61K39/461A61K39/4621A61K39/46434A61K39/4644A61K38/2066A61K2035/122A61K2035/124A61P1/00A61P1/16A61P17/00A61P27/02A61P37/02A61P37/06A61K2239/31A61K9/0019
Inventor SONG, SUN UKLEE, MOON HEEKIM, CHUL SOO
Owner SCM LIFESCI CO LTD